{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:55:31Z","timestamp":1778842531318,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007416","name":"Japan Health Sciences Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.bbrc.2012.06.097","type":"journal-article","created":{"date-parts":[[2012,6,23]],"date-time":"2012-06-23T06:37:34Z","timestamp":1340433454000},"page":"257-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A simple, rapid, and sensitive system for the evaluation of anti-viral drugs in rats"],"prefix":"10.1016","volume":"424","author":[{"given":"Xiaoguang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fusako","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumi","family":"Kawaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi N.","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2012.06.097_b0005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.coph.2010.04.011","article-title":"Antiretroviral drugs","volume":"10","author":"De Clercq","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bbrc.2012.06.097_b0010","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2012.06.097_b0015","doi-asserted-by":"crossref","first-page":"9770","DOI":"10.1073\/pnas.91.21.9770","article-title":"Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection","volume":"91","author":"Wild","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2012.06.097_b0020","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm1319","article-title":"Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1","volume":"11","author":"Fatkenheuer","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2012.06.097_b0025","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2012.06.097_b0030","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1126\/science.272.5263.872","article-title":"HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor","volume":"272","author":"Feng","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2012.06.097_b0035","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/S0960-894X(00)00535-7","article-title":"Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes","volume":"10","author":"Tamamura","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbrc.2012.06.097_b0040","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1006\/bbrc.1998.9871","article-title":"A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140","volume":"253","author":"Tamamura","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2012.06.097_b0045","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/anie.200351024","article-title":"Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries","volume":"42","author":"Fujii","year":"2003","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bbrc.2012.06.097_b0050","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1039\/b306613b","article-title":"Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists","volume":"1","author":"Tamamura","year":"2003","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bbrc.2012.06.097_b0055","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2012.06.097_b0060","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2012.06.097_b0065","doi-asserted-by":"crossref","first-page":"8807","DOI":"10.1128\/JVI.02706-05","article-title":"Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients","volume":"80","author":"Labrosse","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.bbrc.2012.06.097_b0070","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1097\/00002030-200209270-00014","article-title":"Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor","volume":"16","author":"Poveda","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.bbrc.2012.06.097_b0075","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/00002030-200105040-00015","article-title":"Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients","volume":"15","author":"Z\u00f6llner","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.bbrc.2012.06.097_b0080","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/jm701109d","article-title":"Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity","volume":"51","author":"Oishi","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2012.06.097_b0085","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/AAC.01211-08","article-title":"SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide","volume":"53","author":"Naito","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2012.06.097_b0090","doi-asserted-by":"crossref","first-page":"9184","DOI":"10.1016\/j.bmc.2008.09.018","article-title":"Identification of minimal sequence for HIV-1 fusion inhibitors","volume":"16","author":"Nishikawa","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbrc.2012.06.097_b0095","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1074\/jbc.M807169200","article-title":"Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20","author":"Izumi","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2012.06.097_b0200","unstructured":"D.K. Davison, R.J. Medinas, S.M. Mosier, T.S. Bowling, M.K. Delmedico, J.J. Dwyer, N. Cammack, M.L. Greenberg, New fusion inhibitor peptides, TRI-999 and TRI-1144, are potent inhibitors of enfuvirtide and T-1249 resistant isolates. in: Program and Abstracts of the 16 th International AIDS Conference, August 13 -18, 2006,Toronto, Canada, Abstract THPE0021."},{"key":"10.1016\/j.bbrc.2012.06.097_b0105","doi-asserted-by":"crossref","first-page":"12772","DOI":"10.1073\/pnas.0701478104","article-title":"Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus","volume":"104","author":"Dwyer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2012.06.097_b0110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0378-4347(00)00619-8","article-title":"Simultaneous determination of Ziagen and its phosphorylated metabolites by ion-pairing high-performance liquid chromatography\u2013tandem mass spectrometry","volume":"754","author":"Fung","year":"2001","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.bbrc.2012.06.097_b0115","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/elps.200305425","article-title":"Capillary electrophoresis-ion trap mass spectrometry analysis of Ziagen and its phosphorylated metabolites","volume":"24","author":"Cai","year":"2003","journal-title":"Electrophoresis"},{"key":"10.1016\/j.bbrc.2012.06.097_b0120","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1073\/pnas.0607414104","article-title":"HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription","volume":"104","author":"Goffinet","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2012.06.097_b0125","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1084\/jem.20011549","article-title":"Progress toward a human CD4\/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1","volume":"195","author":"Keppler","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbrc.2012.06.097_b0130","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/aid.1992.8.403","article-title":"SIV\/HIV recombinants and their use in studying biological properties","volume":"8","author":"Shibata","year":"1992","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.bbrc.2012.06.097_b0135","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1128\/jvi.71.5.3932-3939.1997","article-title":"Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection","volume":"71","author":"Chackerian","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.bbrc.2012.06.097_b0140","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1128\/jvi.66.4.2232-2239.1992","article-title":"Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene","volume":"66","author":"Kimpton","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.bbrc.2012.06.097_b0145","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/381661a0","article-title":"Identification of a major co-receptor for primary isolates of HIV-1","volume":"381","author":"Deng","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2012.06.097_b0150","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1128\/AAC.45.5.1539-1546.2001","article-title":"4\u2032-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro","volume":"45","author":"Kodama","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2012.06.097_b0155","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/JVI.79.2.764-770.2005","article-title":"Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions","volume":"79","author":"Nameki","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.bbrc.2012.06.097_b0160","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1021\/jm049429h","article-title":"Stereoselective synthesis of [l-Arg-l\/d-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131","volume":"48","author":"Tamamura","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2012.06.097_b0165","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.antiviral.2009.07.008","article-title":"Evaluation of antiretrovirals in animal models of HIV infection","volume":"85","author":"Van Rompay","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bbrc.2012.06.097_b0170","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/carcin\/bgr137","article-title":"Thioredoxin-interacting protein suppresses bladder carcinogenesis","volume":"32","author":"Nishizawa","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbrc.2012.06.097_b0175","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/art.24330","article-title":"Stromal cell-derived factor 1\/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model","volume":"60","author":"Kitaori","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bbrc.2012.06.097_b0180","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00042560-199604150-00001","article-title":"Mechanism of anti-HIV activity of negatively charged albumins: biomolecular interaction with the HIV-1 envelope protein gp120","volume":"11","author":"Kuipers","year":"1996","journal-title":"J. Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"key":"10.1016\/j.bbrc.2012.06.097_b0185","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1128\/JVI.79.5.3009-3015.2005","article-title":"Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN\u2013gp120 interaction","volume":"79","author":"Groot","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.bbrc.2012.06.097_b0190","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/infdis\/172.2.380","article-title":"Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro","volume":"172","author":"Harmsen","year":"1995","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bbrc.2012.06.097_b0195","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrmicro1930","article-title":"Viral infection and iron metabolism","volume":"6","author":"Drakesmith","year":"2008","journal-title":"Nat. Rev. Microbiol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X12011928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X12011928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:00:49Z","timestamp":1757761249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X12011928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0006291X12011928"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2012.06.097","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A simple, rapid, and sensitive system for the evaluation of anti-viral drugs in rats","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2012.06.097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}